T2DM & CV outcomes: More than glucose management? - Lessons from GLP-1RA trials
EuroPrevent 2019 Prof. Jacob discusses the shift in management of diabetes based on CVOTs and explains underlying mechanisms of benefits with GLP-1RAs in diabetic patients.
Video navigation menu
- Is reducing HbA1c really succesful in diabetes? 1:47
- Cardiovascular outcomes trials 3:53
- Underlying mechanisms of CV benefits with GLP-1RAs 6:48
- New recommendations for T2DM patients 9:11
This lecture by prof. Stephan Jacob was part of a CME accredited symposium "The preventive challenge in diabetes & CVD - A multidisciplinary approach"
Prof. Stephan Jacob, endocrinologist/diabetologist, University of Tübingen and Cardio Metabolic Institute, Villingen-Schwenningen, Germany
This recording was independently developed under auspices of EPCCS. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of EPCCS.
Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk.
Share this page with your colleagues and friends: